Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705.
Hotta K, Kiura K, Takigawa N, Yoshioka H, Hayashi H, Fukuyama H, Nishiyama A, Yokoyama T, Kuyama S, Umemura S, Kato Y, Nogami N, Segawa Y, Yasugi M, Tabata M, Tanimoto M. Hotta K, et al. Among authors: kuyama s. J Thorac Oncol. 2010 Oct;5(10):1668-72. doi: 10.1097/JTO.0b013e3181f1c8cb. J Thorac Oncol. 2010. PMID: 20871267 Free article.
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H, Tanimoto M; Okayama Lung Cancer Study Group. Kiura K, et al. Among authors: kuyama s. J Thorac Oncol. 2007 Jan;2(1):44-50. doi: 10.1097/JTO.0b013e31802bafe2. J Thorac Oncol. 2007. PMID: 17410009 Free article. Clinical Trial.
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M. Tabata M, et al. Among authors: kuyama s. Cancer Chemother Pharmacol. 2007 Jun;60(1):1-6. doi: 10.1007/s00280-006-0336-0. Epub 2007 Mar 29. Cancer Chemother Pharmacol. 2007. PMID: 17393168 Clinical Trial.
A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T, Hotta K, Takigawa N, Tada A, Ueoka H, Harita S, Kiura K, Tabata M, Segawa Y, Nogami N, Kuyama S, Shinkai T, Tanimoto M. Shibayama T, et al. Among authors: kuyama s. Lung Cancer. 2006 Aug;53(2):189-95. doi: 10.1016/j.lungcan.2006.05.008. Epub 2006 Jun 27. Lung Cancer. 2006. PMID: 16806573 Clinical Trial.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
106 results